Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:SNY
CUSIPN/A
Phone33-1-53-77-44-00
Debt
Debt-to-Equity Ratio0.25
Current Ratio1.70
Quick Ratio1.26
Price-To-Earnings
Trailing P/E Ratio12.44
Forward P/E Ratio12.18
P/E Growth1.89
Sales & Book Value
Annual Sales$39.60 billion
Price / Sales2.48
Cash Flow$4.6714 per share
Price / Cash8.37
Book Value$26.11 per share
Price / Book1.50
Profitability
EPS (Most Recent Fiscal Year)$3.13
Net Income$4.28 billion
Net Margins10.93%
Return on Equity24.45%
Return on Assets14.07%
Miscellaneous
Employees106,566
Outstanding Shares2,508,090,000
Sanofi (NYSE:SNY) Frequently Asked Questions
What is Sanofi's stock symbol?
Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."
How often does Sanofi pay dividends? What is the dividend yield for Sanofi?
Sanofi declared an annual dividend on Tuesday, February 13th. Shareholders of record on Thursday, May 10th will be given a dividend of $1.8609 per share on Monday, June 4th. This represents a yield of 4.72%. The ex-dividend date is Wednesday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.58. View Sanofi's Dividend History.
How were Sanofi's earnings last quarter?
Sanofi SA (NYSE:SNY) posted its quarterly earnings results on Friday, April, 27th. The company reported $0.79 EPS for the quarter, beating the Zacks' consensus estimate of $0.74 by $0.05. The business earned $7.90 billion during the quarter, compared to analysts' expectations of $7.88 billion. Sanofi had a return on equity of 24.45% and a net margin of 10.93%. The firm's revenue for the quarter was down 8.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.42 earnings per share. View Sanofi's Earnings History.
When is Sanofi's next earnings date?
What guidance has Sanofi issued on next quarter's earnings?
Sanofi updated its second quarter earnings guidance on Friday, April, 27th. The company provided earnings per share guidance of EUR 1.28 for the period, compared to the Thomson Reuters consensus estimate of $1.15.
What price target have analysts set for SNY?
11 Wall Street analysts have issued 1 year target prices for Sanofi's stock. Their predictions range from $45.00 to $55.00. On average, they anticipate Sanofi's share price to reach $49.3333 in the next twelve months. View Analyst Ratings for Sanofi.
What are Wall Street analysts saying about Sanofi stock?
Here are some recent quotes from research analysts about Sanofi stock:
- 1. According to Zacks Investment Research, "Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. Particularly, we are optimistic on sales prospects of Dupixent, which could prove to be an important growth driver. The acquisitions of Ablynx and Bioverativ have strengthened Sanofi’s position in the rare blood disorders market. However, Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan. Other headwinds include generic competition for many drugs and slower-than-expected uptake of new products like Praluent. Meanwhile, the performance of the Vaccines and Consumer Healthcare franchises has been soft lately. Shares have also underperformed the industry this year so far. Nonetheless, Sanofi expects to return to growth in the second half of 2018." (6/13/2018)
- 2. Argus analysts commented, "The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions," the analyst said.See also: Where Does Zika Virus Vaccine Research Stand Now? FY18 ExpectationsArgus expects the company's 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim's consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives."In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company's cost-savings program to benefit margins," (9/1/2017)
Who are some of Sanofi's key competitors?
Some companies that are related to Sanofi include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).
Who are Sanofi's key executives?
Sanofi's management team includes the folowing people:
- Mr. Olivier Brandicourt, CEO & Director (Age 62)
- Mr. Jérôme Contamine, CFO & Exec. VP (Age 61)
- Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
- Mr. Bruno Ménard, Chief Information officer
- Mr. George Grofik, Head of Investor Relations
Has Sanofi been receiving favorable news coverage?
Media coverage about SNY stock has trended positive this week, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sanofi earned a coverage optimism score of 0.48 on Accern's scale. They also gave press coverage about the company an impact score of 45.56 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Sanofi's major shareholders?
Sanofi's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Barrow Hanley Mewhinney & Strauss LLC (0.86%), Franklin Resources Inc. (0.83%), Fisher Asset Management LLC (0.60%), BlackRock Inc. (0.13%), Wells Fargo & Company MN (0.11%) and Federated Investors Inc. PA (0.09%). View Institutional Ownership Trends for Sanofi.
Which major investors are selling Sanofi stock?
SNY stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Senzar Asset Management LLC, Federated Investors Inc. PA, Sei Investments Co., Envestnet Asset Management Inc., Russell Investments Group Ltd., Eversept Partners LLC and Jane Street Group LLC. View Insider Buying and Selling for Sanofi.
Which major investors are buying Sanofi stock?
SNY stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Sio Capital Management LLC, Willis Investment Counsel, Sensato Investors LLC, BlackRock Inc., Summit Trail Advisors LLC, CIBC World Markets Inc. and Point72 Asset Management L.P.. View Insider Buying and Selling for Sanofi.
How do I buy shares of Sanofi?
Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sanofi's stock price today?
One share of SNY stock can currently be purchased for approximately $39.05.
How big of a company is Sanofi?
Sanofi has a market capitalization of $100.17 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. Sanofi employs 106,566 workers across the globe.
How can I contact Sanofi?
Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]
MarketBeat Community Rating for Sanofi (SNY)
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
